
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 999 | 999 | 922 | 1243 | 1713 | 1945 |
Fund Return | -0.12% | -0.12% | -7.8% | 7.52% | 11.37% | 6.88% |
Place in category | 91 | 91 | 131 | 2 | 13 | 34 |
% in Category | 47 | 47 | 72 | 2 | 10 | 33 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity 500 Index Institutional Pr | 597.55B | -4.28 | 9.05 | 12.49 | ||
Fidelity Contrafund | 133.27B | -4.05 | 13.09 | 14.36 | ||
Fidelity Total Market Index Instl b | 100.03B | -4.87 | 8.14 | 11.74 | ||
Fidelity International Index Inst | 56.32B | 7.95 | 6.78 | 5.63 | ||
Fidelity Blue Chip Growth | 54.94B | -13.06 | 10.03 | 15.84 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Health Care Adm | 34.63B | 0.63 | 2.20 | 6.39 | ||
T. Rowe Price Health Sciences | 6.8B | -0.04 | 0.26 | 7.27 | ||
Fidelity Select Health Care | 6.42B | -1.03 | 1.10 | 6.91 | ||
Vanguard Health Care Inv | 6.25B | 0.62 | 2.15 | 6.34 | ||
T. Rowe Price Health Sciences I | 4.79B | 0.00 | 0.39 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 26.72 | 757.18 | +0.38% | |
Novo Nordisk ADR | US6701002056 | 14.35 | 64.49 | -2.38% | |
AstraZeneca ADR | US0463531089 | 10.37 | 67.87 | -0.21% | |
Merck&Co | US58933Y1055 | 4.91 | 78.39 | -0.99% | |
UCB | BE0003739530 | 4.90 | 142.50 | +2.44% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review